Research in Progress
Principal Investigator: Dr. Logan Wink
Research Description: One in 68 children is diagnosed with an Autism Spectrum Disorder (ASD). Individuals with ASD endure lifelong deficits in social communication and interaction, with restricted patterns of behavior or interests. They often also exhibit associated symptoms including hyperactivity and irritability. Historically, treatment for ASD in children has been most successful in treating these associated symptoms. To date, no medication has been shown in controlled trials to improve the core defining features of ASD. As the population of children, adolescents, and adults with ASD grows, there is a pressing medical need to develop effective and safe treatment for the core features of this disorder, thereby improving outcomes. Dr. Wink and her team will conduct a pilot clinical study of intranasal ketamine, a generic drug, in individuals with ASD to determine its effect on the core features.
CWR funding role: Participating funder
Start date: Started in early 2016
Most recent report: Patient enrollment is proceeding on track, with three patients enrolled so far and a waitlist established.
Anticipated next steps:
→ Data published in a scientific journal and/or presented at a scientific conference
→ Data are supporting off-label clinical use
→ Data leveraged into larger philanthropic or government funding for this treatment